DS
NKGN

David Shaw’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

David Shaw’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-252,656
Closed -$2.56M – 4648
2023
Q1 		$2.56M Hold
252,656
– – ﹤0.01% 2498
2022
Q4 		$2.51M Hold
252,656
– – ﹤0.01% 2741
2022
Q3 		$2.46M Hold
252,656
– – ﹤0.01% 2808
2022
Q2 		$2.45M Hold
252,656
– – ﹤0.01% 2894
2022
Q1 		$2.45M Hold
252,656
– – ﹤0.01% 3113
2021
Q4 		$2.45M Hold
252,656
– – ﹤0.01% 3170
2021
Q3 		$2.45M Buy
+252,656
New +$2.46M ﹤0.01% 2845

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

David Shaw's NKGN Position: Q2 2023 in Review

David Shaw sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 252,656 shares — an estimated $2.56M sold.

David Shaw first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $2.56M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • David Shaw reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • David Shaw sold 252,656 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $2.56M.
  • David Shaw first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • David Shaw's NKGen Biotech, Inc. Common Stock position peaked at $2.56M in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.